The International Neuroblastoma Risk Group (INRG) classification system is currently being used as a consensus approach for pretreatment risk classification by the clinical features, tumor histology and molecular markers, particularly MYCN status [7,8,9]. This evidence concerns the gene MYCN and neoplasm.